Match tier
Listed
Presence
Current · Arkansas
Last published
2026
Sources
OpenAlex · ORCID
Refreshed
2026-08-15
C
Carolina Schinke
High Impact
Associate Professor
Also affiliated: Albert Einstein College of Medicine (2008–2024); Cone Health (2018); Montefiore Medical Center (2013–2024); The University of Texas MD Anderson Cancer Center (2023); Emory University (2023); Yeshiva University (2013); Medical College of Wisconsin (2025); University of Arkansas Medical Center (2016–2023); Jacobi Medical Center (2013); University Medical Center Utrecht (2019); Piedmont Cancer Institute (2023); Cancer Research And Biostatistics (2015); Myeloma UK (2017–2018); Winthrop Rockefeller Foundation (2019–2026); The US Oncology Network (2023); International Myeloma Foundation (2015–2019); Arkansas Department of Agriculture (2016); Montefiore Einstein Comprehensive Cancer Center (2024)
Faculty Researcher
Internal Med, College of Medicine
39 h-index
382 pubs
5,344 cited
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Dr. Carolina Schinke's research focuses on plasma cell dyscrasias, including multiple myeloma, monoclonal gammopathy of undetermined significance (MGUS), plasma cell leukemia, and amyloid disease. Her work investigates the molecular underpinnings and evolutionary pathways of these conditions, examining how they progress from smoldering myeloma to more advanced states.
Her recent publications explore the risk of infections associated with bispecific antibodies in multiple myeloma treatment, the safety and efficacy of novel therapies like teclistamab and talquetamab, and disparities in access to advanced treatments such as CAR-T cells and bispecific antibodies. Dr. Schinke also studies the role of the immune microenvironment in multiple myeloma progression at a single-cell level.
Schinke holds an h-index of 38 with over 5,000 citations across 377 publications. She is an Associate Professor of Medicine at the Myeloma Institute for Research and Therapy at the University of Arkansas for Medical Sciences, where she leads a research group and collaborates with several colleagues within the institution.
Research Overview
Dr. Carolina Schinke is an Associate Professor of Medicine at the Myeloma Institute for Research and Therapy at UAMS and joined the department in 2014. She completed her fellowship in Hematology/Oncology in 2013 at Montefiore Medical Center in New York and performed a research fellowship in molecular and translational science at Einstein, New York in 2014 . She earned her medical degree at the University of Halle in Germany and completed her residency at the Jacobi Medical Center in New York in 2010. Dr. Schinke has several publications and scientific poster presentations/abstracts and is a member of the American Society of Hematology, American Society of Oncology and International Myeloma Society. Her clinical interests are plasma cell dyscrasias, including MGUS, smoldering multiple myeloma, plasma cell leukemia as well as amyloid disease and Waldenstroms.
Metrics
- h-index: 39
- Publications: 382
- Citations: 5,344
Selected Publications
-
Insights and Future Directions of GPRC5D Therapies in Multiple Myeloma (2026)
-
Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients (2026)
-
Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells (2026)
-
Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells (2026)
-
Pyrimethamine overcomes resistance to hypomethylating agents by reducing de novo pyrimidine synthesis (2026)
-
Reassessing the Duration of Induction Therapy for Newly Diagnosed, Transplant‐Eligible Myeloma Patients in the Context of Quadruple <scp>CD38</scp> Monoclonal Antibody‐Based Regimens: Is 24 Weeks Optimal? (2026)
-
Peripheral blood immune cell profiling and response to BCMA CAR-T cell therapy in relapsed refractory multiple myeloma (2026)
-
Sustained remission following limited duration of bispecific antibody therapy in patients with relapsed/refractory multiple myeloma (2025)
-
Interim analysis of LimiTec, a prospective trial of limited-duration teclistamab for relapsed/refractory multiple myeloma (2025)
-
Comparative Efficacy of Talquetamab vs. Real-World Physician’s Choice of Treatment in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: Updated Analyses of MonumenTAL-1 vs. LocoMMotion/MoMMent (2025)
-
Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study (2025)
-
Characterization and Management of Cytokine Release Syndrome From the <scp>MonumenTAL</scp> ‐1 Study of Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma (2025)
-
Infections and parameters of humoral immunity with talquetamab in relapsed/refractory multiple myeloma in MonumenTAL-1 (2025)
-
Healing of lytic lesions and restoration of bone health in multiple myeloma through sclerostin inhibition (2025)
-
The efficacy of teclistamab in patients with multiple myeloma and secondary plasma cell leukemia (2025)
Grants & Funding
As listed on this researcher's institutional profile.
- MAGNETISMM-4 A Phase 1b/2, Open Label Umbrella Study of Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA) CD3 Bispecific Antibody, in Combination with Other Anti-Cancer Treatments in Participants with Multiple Myeloma Pfizer, Inc. via ICON Clinical Research Principal Investigator
- A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE AND ELRANATAMAB IN COMBINATION WITH PF-07901801 IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA Pfizer, Inc. Principal Investigator
- Center for Studies of Host Response to Cancer Therapy NIH Co-Investigator
- RC Pilot Award UAMS College of Medicine Principal Investigator
Collaboration Network
Top Collaborators
Sharmilan Thanendrarajan
University of Arkansas for Medical Sciences
30 shared publications
In database
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
- Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
- Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
Showing 5 of 30 shared publications
Maurizio Zangari
University of Arkansas for Medical Sciences
30 shared publications
In database
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
- Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
- Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
Showing 5 of 30 shared publications
Frits van Rhee
University of Arkansas for Medical Sciences
29 shared publications
In database
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
- Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
- Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
Showing 5 of 29 shared publications
Samer Al Hadidi
University of Arkansas for Medical Sciences
21 shared publications
In database
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
- Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
- Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level
- Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor–T Cell Therapy for Hematological Malignant Neoplasms
Showing 5 of 21 shared publications
Leo Rasche
Universitätsklinikum Würzburg (DE)
13 shared publications
- Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed/refractory multiple myeloma (RRMM).
- The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
- Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1–2 study
- Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level
- Updated Results of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma with Prior Exposure to T-Cell Redirecting Therapies: Results of the Phase 1/2 MonumenTAL-1 Study
Showing 5 of 13 shared publications
Cody Ashby
Winthrop Rockefeller Foundation
12 shared publications
In database
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- Epigenomic translocation of H3K4me3 broad domains over oncogenes following hijacking of super-enhancers
Showing 5 of 12 shared publications
Meera Mohan
12 shared publications
- Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma
- Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
- Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy
- Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma
Showing 5 of 12 shared publications
John D. Shaughnessy
University of Arkansas for Medical Sciences
10 shared publications
In database
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Risk of Infections Associated with the Use of Bispecific Antibodies in Multiple Myeloma: A Pooled Analysis
- A gene signature can predict risk of MGUS progressing to multiple myeloma
Showing 5 of 10 shared publications
Michela Campagna
10 shared publications
- Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed/refractory multiple myeloma (RRMM).
- Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1–2 study
- Updated Results of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma with Prior Exposure to T-Cell Redirecting Therapies: Results of the Phase 1/2 MonumenTAL-1 Study
- Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 Results from MonumenTAL-1
- S191: PIVOTAL PHASE 2 MONUMENTAL-1 RESULTS OF TALQUETAMAB (TAL), A GPRC5DXCD3 BISPECIFIC ANTIBODY (BSAB), FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Showing 5 of 10 shared publications
Tara Masterson
Janssen (United States) (US)
10 shared publications
- Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed/refractory multiple myeloma (RRMM).
- Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1–2 study
- Updated Results of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma with Prior Exposure to T-Cell Redirecting Therapies: Results of the Phase 1/2 MonumenTAL-1 Study
- Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 Results from MonumenTAL-1
- S191: PIVOTAL PHASE 2 MONUMENTAL-1 RESULTS OF TALQUETAMAB (TAL), A GPRC5DXCD3 BISPECIFIC ANTIBODY (BSAB), FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Showing 5 of 10 shared publications
Fenghuang Zhan
University of Arkansas for Medical Sciences
9 shared publications
In database
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
- Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Risk of Infections Associated with the Use of Bispecific Antibodies in Multiple Myeloma: A Pooled Analysis
Showing 5 of 9 shared publications
Paula Rodríguez‐Otero
Clinica Universidad de Navarra (ES)
9 shared publications
- Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed/refractory multiple myeloma (RRMM).
- Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1–2 study
- Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 Results from MonumenTAL-1
- S191: PIVOTAL PHASE 2 MONUMENTAL-1 RESULTS OF TALQUETAMAB (TAL), A GPRC5DXCD3 BISPECIFIC ANTIBODY (BSAB), FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
- Analysis of infections and parameters of humoral immunity in patients (pts) with relapsed/refractory multiple myeloma (RRMM) treated with talquetamab (tal) monotherapy in MonumenTAL-1.
Showing 5 of 9 shared publications
Brandi Hilder
Janssen (United States) (US)
9 shared publications
- Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed/refractory multiple myeloma (RRMM).
- Updated Results of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma with Prior Exposure to T-Cell Redirecting Therapies: Results of the Phase 1/2 MonumenTAL-1 Study
- Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 Results from MonumenTAL-1
- S191: PIVOTAL PHASE 2 MONUMENTAL-1 RESULTS OF TALQUETAMAB (TAL), A GPRC5DXCD3 BISPECIFIC ANTIBODY (BSAB), FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
- Analysis of infections and parameters of humoral immunity in patients (pts) with relapsed/refractory multiple myeloma (RRMM) treated with talquetamab (tal) monotherapy in MonumenTAL-1.
Showing 5 of 9 shared publications
Jaszianne Tolbert
Janssen (United States) (US)
9 shared publications
- Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed/refractory multiple myeloma (RRMM).
- Updated Results of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma with Prior Exposure to T-Cell Redirecting Therapies: Results of the Phase 1/2 MonumenTAL-1 Study
- Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 Results from MonumenTAL-1
- S191: PIVOTAL PHASE 2 MONUMENTAL-1 RESULTS OF TALQUETAMAB (TAL), A GPRC5DXCD3 BISPECIFIC ANTIBODY (BSAB), FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
- Analysis of infections and parameters of humoral immunity in patients (pts) with relapsed/refractory multiple myeloma (RRMM) treated with talquetamab (tal) monotherapy in MonumenTAL-1.
Showing 5 of 9 shared publications
Thomas Renaud
Janssen (United States) (US)
9 shared publications
- Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed/refractory multiple myeloma (RRMM).
- Updated Results of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma with Prior Exposure to T-Cell Redirecting Therapies: Results of the Phase 1/2 MonumenTAL-1 Study
- Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 Results from MonumenTAL-1
- S191: PIVOTAL PHASE 2 MONUMENTAL-1 RESULTS OF TALQUETAMAB (TAL), A GPRC5DXCD3 BISPECIFIC ANTIBODY (BSAB), FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
- Analysis of infections and parameters of humoral immunity in patients (pts) with relapsed/refractory multiple myeloma (RRMM) treated with talquetamab (tal) monotherapy in MonumenTAL-1.
Showing 5 of 9 shared publications
Similar Researchers
Based on overlapping research topics
Sharmilan Thanendrarajan
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer-related molecular mechanisms research
Monoclonal and Polyclonal Antibodies Research
Maurizio Zangari
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer-related molecular mechanisms research
CAR-T cell therapy research
John D. Shaughnessy
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer-related molecular mechanisms research
CAR-T cell therapy research
Guido Tricot
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer-related molecular mechanisms research
CAR-T cell therapy research
Bailu Peng
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer-related molecular mechanisms research
CAR-T cell therapy research
Samer Al Hadidi
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
CAR-T cell therapy research
Monoclonal and Polyclonal Antibodies Research